Cargando…
Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass
PURPOSE: To evaluate the contribution of ursodeoxycholic acid (UDCA) in the first 12 months after Roux-en-Y gastric bypass in the prevention of gallstone formation. METHODS: A community-based clinical trial was conducted. A total of 137 patients were included in the study; 69 were treated with UDCA,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira para o Desenvolvimento da Pesquisa em
Cirurgia
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585928/ https://www.ncbi.nlm.nih.gov/pubmed/30785510 http://dx.doi.org/10.1590/s0102-865020190010000009 |
_version_ | 1783428806284935168 |
---|---|
author | Machado, Francisco Heine Ferreira de Castro, Heladio Feitosa Babadopulos, Rodrigo Feitosa de Albuquerque Lima Rocha, Hermano Alexandre Lima Rocha, José Lima de Carvalho de Moraes, Manoel Odorico |
author_facet | Machado, Francisco Heine Ferreira de Castro, Heladio Feitosa Babadopulos, Rodrigo Feitosa de Albuquerque Lima Rocha, Hermano Alexandre Lima Rocha, José Lima de Carvalho de Moraes, Manoel Odorico |
author_sort | Machado, Francisco Heine Ferreira |
collection | PubMed |
description | PURPOSE: To evaluate the contribution of ursodeoxycholic acid (UDCA) in the first 12 months after Roux-en-Y gastric bypass in the prevention of gallstone formation. METHODS: A community-based clinical trial was conducted. A total of 137 patients were included in the study; 69 were treated with UDCA, starting 30 days after the surgery, at a dose of 150 mg twice daily (300 mg/day) over a period of 5 consecutive months (GROUP A), and 68 were control patients (GROUP B). The patients were followed-up, and ultrasonography was performed to determine the presence of gallstones at various times during follow-up. Demographic, anthropometric and comorbid indicators were obtained. The data were subjected to normality tests and evaluated using appropriate tests. RESULTS: Patients did not differ in their baseline characteristics. Of the 69 patients who used UDCA, only one patient developed cholelithiasis (1%), whereas 18 controls (26%) formed gallstones (OR = 24.4, p <0.001). Also, other factors were found not to influence the formation of calculi, such as pre-operative or postoperative hepatic steatosis or diabetes (p = 0.759, 0.468, 0.956). CONCLUSION: The results demonstrated that patients who did not use UDCA showed a 24.4-fold greater probability of developing cholelithiasis. |
format | Online Article Text |
id | pubmed-6585928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Sociedade Brasileira para o Desenvolvimento da Pesquisa em
Cirurgia |
record_format | MEDLINE/PubMed |
spelling | pubmed-65859282019-07-02 Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass Machado, Francisco Heine Ferreira de Castro, Heladio Feitosa Babadopulos, Rodrigo Feitosa de Albuquerque Lima Rocha, Hermano Alexandre Lima Rocha, José Lima de Carvalho de Moraes, Manoel Odorico Acta Cir Bras ORIGINAL ARTICLES PURPOSE: To evaluate the contribution of ursodeoxycholic acid (UDCA) in the first 12 months after Roux-en-Y gastric bypass in the prevention of gallstone formation. METHODS: A community-based clinical trial was conducted. A total of 137 patients were included in the study; 69 were treated with UDCA, starting 30 days after the surgery, at a dose of 150 mg twice daily (300 mg/day) over a period of 5 consecutive months (GROUP A), and 68 were control patients (GROUP B). The patients were followed-up, and ultrasonography was performed to determine the presence of gallstones at various times during follow-up. Demographic, anthropometric and comorbid indicators were obtained. The data were subjected to normality tests and evaluated using appropriate tests. RESULTS: Patients did not differ in their baseline characteristics. Of the 69 patients who used UDCA, only one patient developed cholelithiasis (1%), whereas 18 controls (26%) formed gallstones (OR = 24.4, p <0.001). Also, other factors were found not to influence the formation of calculi, such as pre-operative or postoperative hepatic steatosis or diabetes (p = 0.759, 0.468, 0.956). CONCLUSION: The results demonstrated that patients who did not use UDCA showed a 24.4-fold greater probability of developing cholelithiasis. Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2019-02-14 /pmc/articles/PMC6585928/ /pubmed/30785510 http://dx.doi.org/10.1590/s0102-865020190010000009 Text en https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | ORIGINAL ARTICLES Machado, Francisco Heine Ferreira de Castro, Heladio Feitosa Babadopulos, Rodrigo Feitosa de Albuquerque Lima Rocha, Hermano Alexandre Lima Rocha, José Lima de Carvalho de Moraes, Manoel Odorico Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass |
title | Ursodeoxycholic acid in the prevention of gallstones in patients
subjected to Roux-en-Y gastric bypass
|
title_full | Ursodeoxycholic acid in the prevention of gallstones in patients
subjected to Roux-en-Y gastric bypass
|
title_fullStr | Ursodeoxycholic acid in the prevention of gallstones in patients
subjected to Roux-en-Y gastric bypass
|
title_full_unstemmed | Ursodeoxycholic acid in the prevention of gallstones in patients
subjected to Roux-en-Y gastric bypass
|
title_short | Ursodeoxycholic acid in the prevention of gallstones in patients
subjected to Roux-en-Y gastric bypass
|
title_sort | ursodeoxycholic acid in the prevention of gallstones in patients
subjected to roux-en-y gastric bypass |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585928/ https://www.ncbi.nlm.nih.gov/pubmed/30785510 http://dx.doi.org/10.1590/s0102-865020190010000009 |
work_keys_str_mv | AT machadofranciscoheineferreira ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass AT decastroheladiofeitosa ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass AT babadopulosrodrigofeitosadealbuquerquelima ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass AT rochahermanoalexandrelima ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass AT rochajoselimadecarvalho ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass AT demoraesmanoelodorico ursodeoxycholicacidinthepreventionofgallstonesinpatientssubjectedtorouxenygastricbypass |